59 Result(s)

Article

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

We studied 351 patients with smoldering multiple myeloma (SMM) in whom the underlying primary molecular cytogenetic subtype could be determined based on cytoplasmic immunoglobulin fluorescent in situ hybridizatio...

S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson… in Leukemia (2013)

Article

Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients

The purpose of this study was to determine if there is an increased risk of acute leukemia and myelodysplastic syndromes (MDS) in persons with monoclonal gammopathy of undetermined significance (MGUS). We used...

L E Roeker, D R Larson, R A Kyle, S Kumar, A Dispenzieri, S V Rajkumar in Leukemia (2013)

Article

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of pro...

J T Larsen, S K Kumar, A Dispenzieri, R A Kyle, J A Katzmann, S V Rajkumar in Leukemia (2013)

Article

Treatment patterns and outcomes in elderly patients with multiple myeloma

S-M Bang, R A Kyle, S V Rajkumar, S Kumar in Leukemia (2013)

Article

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary P...

C Fernández de Larrea, R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole… in Leukemia (2013)

Article

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Smoldering multiple myeloma (SMM) carries a 50% risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high ...

G Bianchi, R A Kyle, D R Larson, T E Witzig, S Kumar, A Dispenzieri, W G Morice… in Leukemia (2013)

Article

Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma

A J Greenberg, A M Lee, D J Serie, S K McDonnell, J R Cerhan, M Liebow… in Leukemia (2013)

Article

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair...

J A Katzmann, R Clark, R A Kyle, D R Larson, T M Therneau, L J Melton III… in Leukemia (2013)

Article

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

This manuscript summarizes the recommendations that emerged from the first Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis (AL), a meeting sponsored by the Amyloidosis Foundation (Cla...

R L Comenzo, D Reece, G Palladini, D Seldin, V Sanchorawala, H Landau, R Falk… in Leukemia (2012)

Article

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this diso...

M A Gertz, C B Reeder, R A Kyle, S M Ansell in Bone Marrow Transplantation (2012)

Article

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n=...

A Mahindra, M E Kalaycio, J Vela-Ojeda, D H Vesole, M-J Zhang, P Li… in Leukemia (2012)

Article

Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma

O Landgren, W Ma, R A Kyle, S V Rajkumar, N Korde, M Albitar in Leukemia (2012)

Article

Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma

P Kapoor, S Kumar, S J Mandrekar, K M Laumann, A Dispenzieri, M Q Lacy… in Leukemia (2011)

Article

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD)...

K Detweiler Short, S V Rajkumar, D Larson, F Buadi, S Hayman, A Dispenzieri… in Leukemia (2011)

Article

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence. Although there is agreement ...

P Kapoor, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, D Dingli… in Leukemia (2011)

Article

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma

Elevated immunoglobulin free light chain (FLC) level and abnormal FLC ratio are commonly seen in multiple myeloma (MM) and have prognostic implications. We hypothesized that presence of immunoglobin heavy chai...

S Kumar, L Zhang, A Dispenzieri, S Van Wier, J A Katzmann, M Snyder, E Blood… in Leukemia (2010)

Article

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldens...

R A Kyle, B G M Durie, S V Rajkumar, O Landgren, J Blade, G Merlini, N Kröger… in Leukemia (2010)

Article

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

Bone disease in myeloma occurs as a result of complex interactions between myeloma cells and the bone marrow microenvironment. A custom-built DNA single nucleotide polymorphism (SNP) chip containing 3404 SNPs ...

B G M Durie, B Van Ness, C Ramos, O Stephens, M Haznadar, A Hoering, J Haessler… in Leukemia (2009)

Article

Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

The international staging system (ISS) for multiple myeloma (MM) is a validated alternative to the Durie–Salmon staging system (DSS) for predicting survival at diagnosis. We compared these staging systems for ...

P N Hari, M-J Zhang, V Roy, W S Pérez, A Bashey, L B To, G Elfenbein… in Leukemia (2009)